A consortium of the Dutch university medical centres including Radboudumc, technical universities, health insurer VGZ, medical device manufacturer Nolato Unitron, Stichting Santiago, and life sciences investor Thuja Capital proudly announce the launch of the new TTT MedTech program with Magnolia MedTech Fund (Magnolia). The programme supports early early-stage medical technology (medtech) companies spinning out of Dutch universities and knowledge institutes. The fund is dedicated to investing in early-stage medical technology (medtech) spinoff companies.
The Netherlands produce excellent medtech inventions. But the earliest and riskiest phase from university technology to investable company, has become increasingly difficult to finance. TTT and Magnolia are specifically built to fill that gap, bringing together specialist capital with the knowledge institutes, healthcare system and industry expertise needed to get those technologies to patients.
The initiative responds to a gap that the Dutch MedTech Growth Plan (December 2025) identified: most of the Netherlands’ dedicated medtech funds have ceased operations in recent years, and Europe attracts only 5% of global venture capital against 52% in the US, leaving many promising Dutch spin-outs short of the capital needed to reach patients. By giving these innovations an early, dedicated source of both capital and expert knowledge, the consortium is intended to help more research make it out of the lab and into products that can impact patients’ lives.
“The Netherlands have everything it takes to be a global leader in medical innovation", said . TTT and the Magnolia MedTech Fund helps accelerate this ambition by bringing together researchers, entrepreneurs, investors and healthcare organisations. In this way, we increase the societal impact of Dutch innovations while strengthening our innovation ecosystem.”
Read the full release on the TTT website: Actualities - Thematische Technologie Transfer
